April 29, 2019
A report from IQVIA has identified eight drivers of clinical development the company says will reach “peak impact” over the next two to four years.
- Digital health technologies will capture drug efficacy and safety data remotely to improve patient safety, enable virtual trial formats and ease site burdens.
- The availability of pre-screened patient pools and direct-to-patient recruitment will enable trials to meet enrollment targets, decrease trial duration and accelerate market availability.
- Predictive analytics and artificial intelligence technologies and methods will help identify new clinical hypotheses, reduce trial risk and speed enrollment by identifying protocol-ready patients.
- Increased focus on patient-reported outcomes will provide new insight into the patient experience, including drug efficacy and safety outside the clinical setting.
- Real-world data will contribute to all aspects of accelerating clinical trials, from optimizing trial design to site selection, and will drive real-world evidence registries and serve as a virtual control arm for trials.
- Use of targeted therapies and next-generation biotherapeutics — which have more than doubled over the past three years — also will speed trials and improve efficacy, as well as success rates. However, longer patient follow-up times will be required.
- Biomarker testing will be used more widely to better target trial patient populations. The field is expected to yield a 34 percent increase across therapy areas and trial phases, with a corresponding success rate of 27 percent.
- Regulatory support for precision medicine, as well as novel trial designs and endpoints, will contribute to accelerated drug approvals.
Read the full report at: https://bit.ly/2XK4OvA.
-By John W. Mitchell